NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Cytek Biosciences, Inc. (CTKB) Stock Analysis

Cytek Biosciences, Inc. (CTKB) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

CTKB

$4.70

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CTKB with… →

CTKB Key Statistics

As of Sep 4, 2026
Trading
Open
$4.67
Previous Close
$4.70
Day's Range
4.62–4.73
52-Week Range
3.28–6.18
Volume
478.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.19
Valuation
Market Cap
$610.92M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
67.14
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.96
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.63
Financials (FY)
Revenue (FY)
$201.49M+0.52%
Net Income (FY)
−$66.54M
Profit marginThe share of revenue left as profit after all costs and taxes.
−38.98%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
129.98M
1-Year Return
+18.09%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
1.32M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CTKB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−6.93%
2025−22.19%
2024−28.84%
2023−10.68%
2022−37.44%
2021 (partial year)−13.01%

As of September 4, 2026.

CTKB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$201.49M−$66.54M−33.0%
2024$200.45M−$6.02M−3.0%
2023$193.02M−$12.15M−6.3%
2022$164.04M$2.58M1.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$201.49M$104.46M−$40.38M−$66.54M−33.0%
2024$200.45M$111.11M−$20.52M−$6.02M−3.0%
2023$193.02M$109.43M−$27.85M−$12.15M−6.3%
2022$164.04M$100.97M−$1.80M$2.58M1.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CTKB Valuation vs Medical Devices Median

Median of 151 stocks
MetricCTKBMedical Devices medianvs median
P/S ratio2.962.981% below
Profit margin−38.98%−1.69%37.3 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Cytek Biosciences, Inc. (CTKB) at $610.92M. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 682.

Over the past 52 weeks the price has ranged from $3.28 to $6.18. The most recent close on file for CTKB is $4.70, dated September 4, 2026. The close was unchanged from the previous session. The latest close sits 43.29% above that 52-week low.

Financial Health

In fiscal 2025, Cytek Biosciences, Inc. reported revenue of $201.49M. That is +0.52% against the prior fiscal year, when revenue was $200.45M. The same year closed with a net loss of $66.54M. Profit margin runs at −38.98%. That is 37.3 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −0.63.

Across the 4 fiscal years on file, revenue moves from $164.04M in 2022 to $201.49M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 67.14. Measured against sales, the shares trade at 2.96 times revenue. On price-to-sales that is 0.69% below the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

Over the trailing twelve months the price has returned +18.09%. Measured over 5 years, that is −27.96% a year compounded. The reported beta is 1.19. Annualized volatility over the trailing 5 years is 63.33%.

Growth & Income

The record shows no dividend for CTKB.

The strongest complete calendar year on file is 2023 at −10.68%; the weakest is 2022 at −37.44%. Of the 4 complete calendar years on file, 0 finished higher. So far in 2026 the price is −6.93%.

Peer Comparison

Cytek Biosciences, Inc. (CTKB) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cytek Biosciences, Inc. CTKB $610.92M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Cytek Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Cytek Biosciences, Inc.

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Visit website →